Inhalation Sciences receive European Patent for XposeALI 3D in vitro cell culturing module
Stockholm, Sweden 8 October: The European Patent Office has granted a patent to XposeALI, ISAB’s in vitro cell culturing module. “XposeALI delivers exceptionally precise, detailed data on how airborne micro- and nanoparticles particles affect cells in the lung, early on—whilst dramatically reducing the number of animals needed in research,” says ISAB CEO Lena Heffler.
XposeALI is PreciseInhale’s 3D cell exposure module. It’s one of a range of modules, in vitro and in vivo, that can be attached to ISAB’s aerosol generator, PreciseInhale to enable control and precision through all stages of lung research. It combines precision aerosol dosing with 3D cell models cultured in an Air Liquid Interface (ALI) – delivering detailed in vitro data on the cellular effects of airborne particulates.
XposeALI was purchased and installed at the institute of environmental medicine at Karolinska Institutet in Stockholm in 2016, where it has been used extensively in research on nano- as well as micro- particle pollutants. Assoc. Professor at the institute, Lena Palmberg: “Culturing 3D models in an Air Liquid Interface mimics the uptake of substances into the lung more exactly than conventional cell culturing. Cost-effective and very precise, it gives toxicologists and environmental researchers precise results that closely mirror in vivo findings.”
ISAB CEO Lena Heffler: “XposeALI was granted a patent in China in November 2017, we’re delighted it has now cleared this crucial milestone here in Europe.”
XposeALI’s European patent number is 61583EP.
For more information about Inhalation Sciences please contact: Lena Heffler, CEO Email: email@example.com Phone: +46 (0)70 205 96 20Press release in PDF format